COVID-19与甲型流感患者在静脉-静脉体外膜氧合期间的急性脑损伤:体外生命支持组织登记数据的倾向性评分匹配分析
该回顾性多中心观察性队列研究基于体外生命支持组织登记数据(2009—2021年,多达534个ECMO中心),纳入2253例接受静脉-静脉ECMO的成人COVID-19或H1N1相关ARDS患者(COVID-19 1916例、H1N1 337例),经倾向性评分匹配后各337例。匹配队列中,COVID-19患者急性脑损伤发生率为10%,H1N1为12%,两组无显著差异(aOR 0.83,95%CI 0.44-1.54,p=0.53);血栓并发症无差异(aOR 0.67,95%CI 0.44-1.02,p=0.06),但COVID-19患者出血并发症更少(aOR 0.27,95%CI 0.17-0.42,p<0.001),死亡率更高(aOR 2.17,95%CI 1.45-3.23,p<0.001)。两组中发生急性脑损伤者死亡率均显著高于未发生者:COVID-19组94% vs 40%(p<0.001),H1N1组75% vs 29%(p<0.001)。
要点
- 匹配队列中COVID-19与H1N1患者急性脑损伤发生率分别为10%与12%,无显著差异(aOR 0.83,95%CI 0.44-1.54,p=0.53)。
- COVID-19患者出血并发症少于H1N1患者(aOR 0.27,95%CI 0.17-0.42,p<0.001),血栓并发症无显著差异(aOR 0.67,95%CI 0.44-1.02,p=0.06)。
- COVID-19患者死亡率高于H1N1患者(aOR 2.17,95%CI 1.45-3.23,p<0.001)。
- 两组中发生急性脑损伤者死亡率均显著升高:COVID-19组94% vs 40%(p<0.001),H1N1组75% vs 29%(p<0.001)。
- 作者指出,COVID-19与H1N1患者在静脉-静脉ECMO期间急性脑损伤频率相似,均为一般历史ARDS接受静脉-静脉ECMO人群的2倍。
适用人群与场景
- 年龄18岁及以上、因COVID-19或H1N1相关ARDS需要静脉-静脉ECMO支持的患者,数据报告至体外生命支持组织,来自2009至2021年间多达534个ECMO中心。
研究设计与关键结果
- 研究类型为回顾性多中心观察性队列研究,数据来自体外生命支持组织登记,2009至2021年多达534个ECMO中心。
- 共纳入2253例静脉-静脉ECMO患者(COVID-19 1916例,H1N1 337例),经倾向性评分匹配后674例(COVID-19 337例,H1N1 337例),中位年龄41岁,55%为男性。
- 主要终点急性脑损伤:匹配队列中COVID-19组10% vs H1N1组12%,无显著差异(aOR 0.83,95%CI 0.44-1.54,p=0.53)。
- 次要终点血栓并发症:COVID-19组 vs H1N1组 aOR 0.67(95%CI 0.44-1.02,p=0.06),无显著差异。
- 次要终点出血并发症:COVID-19组少于H1N1组(aOR 0.27,95%CI 0.17-0.42,p<0.001)。
- 次要终点死亡率:COVID-19组高于H1N1组(aOR 2.17,95%CI 1.45-3.23,p<0.001)。
- 两组中急性脑损伤患者死亡率均高于无急性脑损伤患者:COVID-19组94% vs 40%(p<0.001),H1N1组75% vs 29%(p<0.001)。
证据类型、等级与局限
- 证据类型:回顾性多中心观察性队列研究(体外生命支持组织登记数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COVID-19与H1N1 ARDS均增加静脉-静脉ECMO患者的急性脑损伤频率,且急性脑损伤使两组死亡率均翻倍,提示对两类患者均应关注急性脑损伤。
- 研究显示COVID-19患者出血并发症少于H1N1患者,但死亡率更高,临床管理中需结合原发病因评估风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Limited data exist on outcomes in COVID-19- vs. influenza A (H1N1)-associated acute respiratory distress syndrome (ARDS) patients when supported on venovenous extracorporeal membrane oxygenation (ECMO). We aimed to compare acute brain injury (ABI) frequency, thrombotic, and hemorrhagic complications and mortality in COVID-19- vs. H1N1-associated ARDS patients on venovenous ECMO.
DESIGN: Retrospective multicenter observational cohort study.
SETTING: Data reported to the Extracorporeal Life Support Organization by up to 534 ECMO centers from 2009 to 2021.
PATIENTS: Patients 18 years or older with COVID-19 or H1N1 requiring venovenous ECMO support.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We conducted a retrospective analysis on 2253 venovenous ECMO patients (1916 COVID-19 and 337 H1N1). We employed propensity score matching followed by multivariable logistic regression to compare outcomes. The primary outcome was ABI and secondary outcomes were thrombosis, hemorrhage, and mortality. After matching, 674 patients (337 COVID and 337 H1N1) remained (median age = 41, 55% male). In the matched cohort, 10% of COVID-19 patients experienced ABI compared with 12% of H1N1 patients, with no significant difference between the groups (adjusted odds ratio [aOR], 0.83; 95% CI, 0.44-1.54; p = 0.53). There was no difference in thrombotic complications (aOR, 0.67; 95% CI, 0.44-1.02; p = 0.06), but COVID-19 patients had fewer hemorrhagic complications (aOR, 0.27; 95% CI, 0.17-0.42; p < 0.001) compared with H1N1. Mortality was higher in COVID patients (aOR, 2.17; 95% CI, 1.45-3.23; p < 0.001). In both groups, however, patients with ABI had higher mortality than those without, with 94% vs. 40% ( p < 0.001) for COVID and 75% vs. 29% ( p < 0.001) for H1N1, respectively.
CONCLUSIONS: COVID-19 and H1N1 patients on venovenous ECMO exhibited similar ABI frequency, which was twice that observed in the general historical ARDS patients supported on venovenous ECMO population. Our findings highlight that both COVID and H1N1 ARDS increase ABI frequency in ECMO patients. Finally, the presence of ABI doubled mortality among both COVID and H1N1.
参考来源
- Khanduja S, Sabit A, Etchill E, et al. Acute Brain Injury in COVID-19 Versus Influenza A Patients on Venovenous Extracorporeal Membrane Oxygenation: A Propensity Score Matching Analysis of the Extracorporeal Life Support Organization Registry. Crit Care Med. 2025. PMID: 41134089. doi:10.1097/CCM.0000000000006916
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。